Bull Hedging
  • Politics
  • Stocks
  • Business
  • Investing
  • Politics
  • Stocks
  • Business
  • Investing

Bull Hedging

Politics

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by admin October 3, 2025
October 3, 2025
Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS

previous post
Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin
next post
Reagan-appointed judge, once rebuked by Supreme Court, continues to lambaste Trump

Related Posts

Trump designates Saudi Arabia a major non-NATO ally...

November 19, 2025

John Bolton’s trial still far off as judge...

November 22, 2025

First Mexico-born rep targets indictment-plagued Democrat in House...

April 15, 2025

Trump remains committed to US owning Gaza, says...

February 10, 2025

Who is Neera Tanden? The controversial Dem operative...

June 25, 2025

Hamas agrees to release 10 more hostages

June 1, 2025

Russia batters Ukraine power grid amid rising concern...

December 14, 2024

US Embassy in Israel tells government employees, families...

June 15, 2025

Experts say first week of ‘Trump effect’ is...

January 26, 2025

Trump extends US security guarantee to Qatar, elevating...

October 4, 2025

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio
  • Republican populism craters as Trump stumbles, Democrats surge
  • Trump admin warned to take front seat as UN chief race shifts left, boosting anti-US contenders
  • GOP unveils plan for ‘Trump Health Freedom Accounts’ to replace Obamacare subsidies with state waivers

Recent Comments

No comments to show.

About Us

About Us

Design Magazine

Welcome to Design Magazine. Follow us for daily & updated design tips, guide and knowledge.

Stay Connect

Facebook Twitter Instagram Pinterest Youtube Email

Recent Posts

  • The Real Drivers of This Market: AI, Semis & Robotics

    December 6, 2025
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    December 6, 2025
  • Republican populism craters as Trump stumbles, Democrats surge

    December 6, 2025
  • Trump admin warned to take front seat as UN chief race shifts left, boosting anti-US contenders

    December 6, 2025
  • GOP unveils plan for ‘Trump Health Freedom Accounts’ to replace Obamacare subsidies with state waivers

    December 6, 2025
  • Abortion restrictions create major roadblock for bipartisan Obamacare subsidy deal in Senate

    December 6, 2025

Editors’ Picks

  • 1

    Small Caps are Set to Skyrocket in 2025—Here’s What You Need to Know

    December 12, 2024
  • 2

    Environmental Approval for Boland Infield Studies & Update on Scaled Column ISR Test

    September 19, 2025
  • 3

    Ad revenue should stabilize for media companies in 2025 — if they have sports

    December 31, 2024
  • 4

    Trump leaves China guessing what his next move is with unusual inauguration invitation

    December 15, 2024
  • 5

    Zinc Stocks: 4 Biggest Canadian Companies in 2025

    January 15, 2025
  • 6

    Lead Price Forecast: Top Trends for Lead in 2025

    January 11, 2025
  • 7

    Uranium Price Forecast: Top Trends That Will Affect Uranium in 2025

    December 19, 2024
Promotion Image

banner

Categories

  • Business (602)
  • Investing (2,582)
  • Politics (3,117)
  • Stocks (946)
  • About us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: bullhedging.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2025 bullhedging.com | All Rights Reserved